MM&M

Targeting eosinophilic asthma, AstraZeneca wants HCPs to Move Forward with Fasenra

AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...
The Financial

AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma

The FINANCIAL — AstraZeneca and its global biologics research and development arm, MedImmune, on January 10 announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on ...
Monthly Prescribing Reference

Fasenra Approved for Pediatric Patients With Severe Eosinophilic Asthma

No new safety signals were identified in the pediatric trial. The Food and Drug Administration (FDA) has expanded the approval of Fasenra (benralizumab) for add-on maintenance treatment of severe ...
Business Wire

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...
Healio

Fasenra receives FDA approval for asthma treatment in children aged 6 to 11 years

Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...
FiercePharma

One look: AstraZeneca unifies patient-physician messaging for asthma blockbuster Fasenra

AstraZeneca is refreshing its Fasenra campaign. Almost six years into the launch, the Big Pharma has established consistent messaging across physicians and patients for the first time, tying the brand ...
Benzinga.com

AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation

The FDA approved on Wednesday AstraZeneca Plc’s (NASDAQ:AZN) Fasenra (benralizumab) for eosinophilic granulomatosis with polyangiitis (EGPA), a rare, immune-mediated vasculitis (inflammation of the ...
FiercePharma

AstraZeneca's Fasenra woes continue as it comes up short in eosinophilic esophagitis

Reaching blockbuster status last year for its asthma drug Fasenra, AstraZeneca had high hopes of expanding its label and running down GSK’s rival treatment, Nucala. But Fasenra’s upward trajectory has ...
MediaPost

Pickleball Fights Severe Asthma For AstraZeneca's Fasenra

Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first-ever sports partnership. The brand began ...
Business Wire

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...
Monthly Prescribing Reference

FDA Approves Fasenra for Eosinophilic Granulomatosis With Polyangiitis

During weeks 48 through 52, a 100% reduction in the OCS dose was observed in 41% of benralizumab-treated patients vs 26% of mepolizumab-treated patients. The Food and Drug Administration (FDA) has ...
MM&M

AstraZeneca takes to the pickleball court for Fasenra campaign

Step aside football, basketball and hockey, AstraZeneca is bringing its sports marketing efforts to the fastest-growing sport in America — pickleball. The pharma giant recently announced a partnership ...